The Karmanos Cancer Institute in Detroit is the first center in Michigan approved to treat adult patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) with the commercially approved chimeric antigen receptor (CAR) T-cell therapy. CAR-T therapy is a type of immunotherapy made from a patient’s own white blood cells, which are genetically modified to recognize and attack the patient’s cancer cells. Karmanos Cancer Institute took part in the CAR-T clinical trials that led to the U.S. Food and Drug Administration (FDA) approval of CAR-T therapy for this type of lymphoma in October 2017. Diffuse large B-cell lymphoma is an aggressive disease and the most common form of non-Hodgkin lymphoma (NHL), representing approximately 30 percent of newly diagnosed cases of NHL in the United States. Patients with DLBCL who have not responded to at least two other types of treatment, or who have relapsed following other treatment, may be eligible for CAR-T therapy. Call 800-527-6266.
The Karmanos Cancer Institute in Detroit is the first center in Michigan approved to treat adult patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) with the commercially approved chimeric antigen receptor (CAR) T-cell therapy. CAR-T therapy is a type of immunotherapy made from a patient’s own white blood cells, which are genetically modified to recognize and attack the patient’s cancer cells. Karmanos Cancer Institute took part in the CAR-T clinical trials that led to the U.S. Food and Drug Administration (FDA) approval of CAR-T therapy for this type of lymphoma in October 2017. Diffuse large B-cell lymphoma is an aggressive disease and the most common form of non-Hodgkin lymphoma (NHL), representing approximately 30 percent of newly diagnosed cases of NHL in the United States. Patients with DLBCL who have not responded to at least two other types of treatment, or who have relapsed following other treatment, may be eligible for CAR-T therapy. Call 800-527-6266.